 | ||
Asunaprevir daclatasvir national patient consultation webinar
Asunaprevir (formerly BMS-650032, brand name in Japan and Russia Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It is undergoing development by Bristol-Myers Squibb and is currently in Phase III clinical trials.
Contents
Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.
Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.
How to pronounce asunaprevir
References
Asunaprevir Wikipedia(Text) CC BY-SA